Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
Patent Expiries of the Leading Anticonvulsants Followed by Generics Erosions Will Decline the Anticonvulsants Market by a CAGR of 0.1% in The Future Various anticonvulsants, both branded and off-label are being used for the treatment of many indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder and anxiety. The patents of leading anticonvulsants such as Topamax (topiramate), Trileptal (oxcarbazepine), Depakote (divalproex sodium), Keppra (levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for management of the various indications has caused the emergence of generics for these anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market in the future. Strong Anticonvulsants Product Pipeline Will Drive the Anticonvulsant Market in Future The anticonvulsants product pipeline consists of 23 new molecules in the various stages of clinical trials. Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of the total anticonvulsants product pipeline is in Phase III clincal studies. The majority of these molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant market.
Lyrica Will Be a Market Leader in Anticonvulsants Market in Future Lyrica (pregabalin) is the branded anriconvulsant product of Pfizer.Lyrica is indicated for the treatment of the epilepsy, fibromyalgia and neuropathic pain. Lyrica along with Neurontin (gabapentin) is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.57 billion and $2.84 billion for Pfizer, in 2008 and 2009 respectively. The incresing uptake of Lyrica for the treatment of neuropathic pain and fibromyalgia is expected to make Lyrica the market leader in the anticonvusant market in future. GBI Research, the leading business intelligence provider, has released its latest research, “Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies”, which provides insights into global anticonvulsant market and market forecast until 2016. Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline. For further details, please click or add the below link to your browser: http://gbiresearch.com/Report.aspx?ID=Anti-convulsants-Market-to-2016-Cost-Advantage-and-Dosage-Convenience-Provided-by-Generic-Anticonvulsants-Will-Limit-Commercial-Opportunities-for-Novel-Therapies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.gbiresearch.com For more details contact: firstname.lastname@example.org North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782